Up­dat­ed: Gilead, Ar­cel­lx team up on an­ti-BC­MA CAR-T as biotech touts a 100% re­sponse rate at #ASH22

Gilead and Kite are plunk­ing down big cash to get in­to the an­ti-BC­MA CAR-T game.

The pair will shell out $225 mil­lion in cash up­front and $100 mil­lion in eq­ui­ty to Ar­cel­lx, Kite an­nounced Fri­day morn­ing, to de­vel­op the biotech’s lead CAR-T pro­gram to­geth­er. Kite will han­dle com­mer­cial­iza­tion and co-de­vel­op­ment with Ar­cel­lx, and prof­its in the US will be split 50-50.

Con­cur­rent with the deal, Ar­cel­lx re­vealed its lat­est cut of da­ta for the pro­gram known as CART-ddBC­MA, ahead of a full pre­sen­ta­tion at this week­end’s ASH con­fer­ence — a 100% re­sponse rate among pa­tients get­ting the ther­a­py. In­vestors jumped at the dual an­nounce­ments, send­ing Ar­cel­lx shares $ACLX up more than 25% in Fri­day’s morn­ing ses­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER